Christopher Michael Bull
Keine laufenden Positionen mehr
Karriereverlauf von Christopher Michael Bull
Ehemalige bekannte Positionen von Christopher Michael Bull
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| AFRICAN DAWN CAPITAL LIMITED | Vorsitzender | 31.10.2014 | 12.06.2015 |
| Independent Dir/Board Member | 31.10.2014 | 12.06.2015 | |
Oxyrane UK Ltd.
 Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Direktor/Vorstandsmitglied | - | - |
Ausbildung von Christopher Michael Bull
| University of KwaZulu-Natal | Undergraduate Degree |
Statistik
International
| Südafrika | 3 |
| Vereinigtes Königreich | 2 |
Operativ
| Director/Board Member | 1 |
| Undergraduate Degree | 1 |
| Chairman | 1 |
Sektoral
| Health Technology | 2 |
| Consumer Services | 2 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AFRICAN DAWN CAPITAL LIMITED | Finance |
| Private Unternehmen | 1 |
|---|---|
Oxyrane UK Ltd.
Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Health Technology |
